Ireland procures Sobi therapies for all haemophilia patients

7th February 2018 Uncategorised 0

The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.

More: Ireland procures Sobi therapies for all haemophilia patients
Source: News